Insulin Delivery Devices Market by Type [Insulin Pens (Reusable, Disposable), Insulin Pumps (Tethered, Tubeless), Insulin Pen Needle (Standard, Safety), Insulin Syringes, Others], Application [Type 1 Diabetes, Type 2 Diabetes] - Global Forecast to 2031

Market Size
$16.92B
MARKET SIZE, 2026
Projected Market Size
$26.37B
MARKET SIZE, 2031
CAGR
9.3%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

INSULIN DELIVERY DEVICES MARKET SIZE, SHARE & GROWTH SNAPSHOT

insulin-delivery-device-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global insulin delivery devices market is projected to grow from USD 16.92 billion in 2026 to USD 26.37 billion by 2031, at a CAGR of 9.3% during the forecast period. The market was valued at USD 15.61 billion in 2025. The insulin delivery devices market is driven by rising diabetes prevalence and technological advancements. High device costs, limited reimbursement, and needle anxiety restrain growth. Increasing healthcare expenditure and innovations in smart pens and insulin pumps create opportunities. Meanwhile, needlestick injuries, improper device usage, and affordability barriers remain key challenges.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 15.61 Billion
    Current Market Size (2026): USD 16.92 Billion
    Forecast Market Size (2031): USD 26.37 Billion
    CAGR (2026–2031): 9.3%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for the largest share of 35–37% of the global insulin delivery devices market in 2025.
    Type Leader: Insulin pens accounted for the largest share of 51–52% of the insulin delivery devices market in 2025.
    Application Leader: Type 2 diabetes accounted for the larger share of 82–84% of the insulin delivery devices market in 2025.
    End User Leader: Self/home healthcare accounted for the larger share of 78–80% of the insulin delivery devices market in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Novo Nordisk (Denmark) and Embecta Corp. (US) were recognized as star players due to their strong product portfolios and established geographic presence.
    Sequel Med Tech, LLC (US) (Progressive Company) and ViCentra B.V. (Netherlands) (Responsive Company) have established themselves among startups and SMEs, supported by strong product portfolios and effective business strategies.

The insulin delivery devices market is driven by the rising prevalence of diabetes and technological advancements in insulin administration. However, needle anxiety, high device costs, and limited reimbursement in developing countries restrain market growth. Increasing healthcare expenditure, research and development investments, and innovations in smart insulin pens, wearable pumps, and safety-engineered needles create significant opportunities. Meanwhile, needlestick injuries, improper device usage, and affordability challenges remain key concerns for manufacturers and healthcare providers.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The insulin delivery devices market is shifting toward patient-centric, connected, automated diabetes management devices. Growing adoption of smart insulin pens, wearable insulin pumps, tubeless patch pumps, and automated insulin delivery systems is improving dosing convenience and supporting personalized treatment. Patients increasingly prioritize ease of use, portability, reduced injection discomfort, and independence in home-based care. Healthcare providers are emphasizing accurate insulin administration, improved treatment adherence, and integration with continuous glucose monitoring systems. Additionally, advances in digital health technologies and remote patient monitoring are improving treatment oversight. However, high device costs, affordability constraints, training requirements, and compatibility issues continue to influence adoption across markets.

insulin-delivery-device-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising prevalence of diabetes
  • Technological advancements in insulin delivery devices
RESTRAINTS
Impact
Level
  • High costs and limited reimbursement in developing countries
  • Needle anxiety among patients limiting growth of the pen needle and syringe market
OPPORTUNITIES
Impact
Level
  • Increase in R&D activities and strategic partnerships
  • Increasing healthcare expenditure on diabetes care
CHALLENGES
Impact
Level
  • Needlestick injuries and misuse of injection pens
  • Lack of interoperability among insulin delivery devices

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising prevalence of diabetes

The increasing prevalence of diabetes is a major driver of the insulin delivery devices market, as a growing number of patients require effective insulin administration to manage their condition. Both type 1 diabetes, which requires lifelong insulin therapy, and advanced type 2 diabetes contribute to demand for insulin delivery products. Insulin pens, pen needles, syringes, and insulin pumps provide different administration options depending on patients’ clinical needs. Rising awareness of diabetes management, improved diagnosis, and longer-term treatment requirements further support device demand. Additionally, the growing burden of diabetes across developed and emerging economies is encouraging manufacturers to expand product availability and develop convenient, accurate, and patient-friendly insulin delivery technologies.

Restraint: High costs and limited reimbursement in developing countries

High costs and limited reimbursement in developing countries restrain the growth of the insulin delivery devices market by limiting patient access to advanced treatment technologies. Insulin pumps, automated insulin delivery systems, and smart insulin pens often involve substantial upfront costs, while recurring expenses for cartridges, infusion sets, pen needles, and other consumables increase the overall treatment burden. Limited insurance coverage, inadequate public healthcare funding, and out-of-pocket payment requirements further restrict affordability. Consequently, many patients rely on conventional insulin syringes or delay adopting advanced devices. These financial barriers constrain market penetration, particularly in low-income populations, limiting manufacturers' opportunities to expand sales across developing economies.

Opportunity: Increasing healthcare expenditure on diabetes care

Increasing healthcare expenditure on diabetes care presents a significant opportunity for the insulin delivery devices market by supporting investment in advanced treatment technologies, healthcare infrastructure, and patient management programs. Greater spending by governments, healthcare providers, insurers, and patients can improve access to insulin pens, insulin pumps, safety-engineered needles, and connected delivery systems. Additionally, increasing spending on diabetes education and specialized treatment services can encourage adoption of appropriate insulin-administration technologies. In emerging economies, improvements in healthcare funding and insurance coverage may help address affordability barriers. Furthermore, investments in digital health solutions and automated insulin delivery systems create opportunities for manufacturers to introduce innovative products and expand their customer base.

Challenge: Needlestick injuries and misuse of injection pens

Needlestick injuries and the misuse of injection pens remain important challenges in the insulin delivery devices market, particularly in healthcare settings where multiple patients receive insulin therapy. Accidental needle injuries can expose healthcare professionals and caregivers to bloodborne pathogens, creating occupational safety concerns. Improper injection techniques, incorrect dose selection, inadequate needle disposal, and the reuse or sharing of injection equipment can compromise patient safety. Sharing insulin pens between patients, even when the needle is changed, can transmit bloodborne infections and is not recommended. Manufacturers and healthcare providers must therefore emphasize safety-engineered devices, appropriate training, single-patient use, and correct disposal practices. These requirements can increase training and compliance costs while influencing device selection and procurement decisions.

INSULIN DELIVERY DEVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Novo Nordisk's insulin delivery portfolio includes reusable pens such as NovoPen 6 and NovoPen Echo Plus, as well as prefilled disposable pens such as FlexPen and FlexTouch. These devices are used by patients requiring insulin injections for diabetes management in home healthcare settings and under healthcare-professional supervision. Smart pens record dose information, while dose-setting mechanisms and prefilled designs simplify insulin administration. Supports accurate and convenient insulin administration, simplifies dose selection, and improves visibility into previous injections through connected or memory-enabled pens. Prefilled and reusable options accommodate different patient preferences and treatment requirements.
company logo
embecta provides insulin pen needles, conventional insulin syringes, and safety-engineered injection products. Its portfolio includes Nano pen needles, Ultra-Fine pen needles, AutoShield Duo safety pen needles, and insulin syringes in different needle lengths and barrel capacities. These products support subcutaneous insulin administration by patients at home and healthcare professionals in clinical settings. Offers flexibility in insulin administration through different needle lengths and syringe capacities. Shorter pen needles support a more comfortable injection experience, while safety-engineered products help reduce the risk of accidental needlestick injuries.
company logo
Medtronic's MiniMed insulin pump portfolio includes the MiniMed 780G automated insulin delivery system. The system uses continuous glucose monitoring data to adjust insulin delivery and provide automated correction doses. It is designed for eligible people with diabetes requiring insulin and is used in home-based diabetes management with healthcare-professional guidance. Enables personalized, continuous insulin delivery and automated adjustments based on glucose readings. Integration with glucose sensors can help improve glucose management, reduce the burden of multiple daily injections, and provide patients and care partners with access to diabetes-related information.
company logo
Sanofi offers insulin delivery devices associated with its insulin portfolio, including the SoloStar prefilled disposable pen and reusable pen options such as AllStar and TouStar in India. These devices are used to administer compatible insulin formulations, including Lantus, Toujeo, and Apidra in applicable presentations and markets. They support routine insulin administration for patients with diabetes in home and clinical settings. Provides prefilled and reusable delivery options to accommodate different treatment needs. Features such as dose selection, portability, and a prefilled format can simplify insulin administration and support convenient diabetes management. Device and insulin compatibility varies by product and market.
company logo
Eli Lilly supplies insulin in prefilled delivery devices, including the KwikPen platform used with products such as Humalog, Humulin, and Lyumjev in applicable markets. These pens enable patients requiring insulin therapy to administer prescribed doses through subcutaneous injection, including in home-based settings. Product-specific presentations and indications vary by country. Provides a convenient, prefilled insulin administration format with dose-selection features that can simplify routine injections. Multiple insulin formulations and pen presentations support different prescribed treatment requirements and help patients manage insulin administration outside healthcare facilities.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The insulin delivery devices market ecosystem comprises raw material suppliers, component manufacturers, device manufacturers, pharmaceutical companies, distributors, healthcare providers, and end users. Raw material and component suppliers provide medical-grade plastics, metals, needles, cartridges, sensors, and electronic components required for device manufacturing. Manufacturers such as Novo Nordisk, embecta, Medtronic, Sanofi, and Eli Lilly develop insulin pens, pen needles, syringes, and insulin pump systems. Distributors, pharmacies, and medical supply providers facilitate product availability across healthcare settings. Hospitals, diabetes specialty clinics, and home healthcare users drive demand. Regulatory authorities, reimbursement providers, and technology partners influence product approvals, affordability, innovation, and market adoption.

insulin-delivery-device-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

insulin-delivery-device-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Insulin Delivery Devices Market, By Type

Based on type, the insulin delivery devices market is divided into insulin pens, insulin pumps, insulin pen needles, insulin syringes, and other insulin delivery devices. Among these, the insulin pens segment held the largest market share in 2025. This is due to its convenience, portability, and ease of administration. Insulin pens offer accurate dose selection, reduce preparation time, and provide a more discreet alternative to conventional syringes. The availability of reusable and disposable pens accommodates different patient preferences and affordability requirements. Additionally, compatibility with various insulin formulations, improvements in pen design, and the availability of fine pen needles support widespread adoption among patients requiring regular insulin therapy.

Insulin Delivery Devices Market, By Application

By application, the insulin delivery devices market is divided into type 1 and type 2 diabetes. Among these, the type 2 diabetes segment accounted for the largest share in 2025, as type 2 diabetes accounts for over 90% of diabetes cases worldwide, according to the International Diabetes Federation. Although many patients initially manage the condition through lifestyle modifications and non-insulin medications, disease progression can necessitate insulin therapy. The growing population requiring long-term diabetes management supports demand for insulin pens, syringes, pen needles, and insulin pumps. Increasing diabetes prevalence, expanding diagnosis rates, and rising awareness of treatment options further contribute to segment growth.

Insulin Delivery Devices Market, By End User

Based on end users, the insulin delivery devices market is bifurcated into self/home healthcare and hospitals & diabetes specialty clinics. In 2025, the self/home healthcare segment accounted for the largest share of the market because diabetes requires regular, long-term insulin administration that can often be managed outside healthcare facilities. Insulin pens, syringes, and insulin pumps enable patients to administer insulin independently, reducing the need for frequent hospital visits. The growing availability of user-friendly devices, smart insulin pens, and automated insulin delivery systems further supports home-based diabetes management. Additionally, increasing patient awareness, convenience, and the need to reduce healthcare costs encourage adoption of insulin delivery devices in home healthcare settings.

REGION

North America held the largest share of the insulin delivery devices market in 2025

North America held the largest share of the insulin delivery devices market in 2025, driven by the substantial diabetes population, high healthcare expenditure, and advanced healthcare infrastructure. The region benefits from widespread adoption of insulin pens, insulin pumps, and automated insulin delivery systems. Established reimbursement mechanisms, including coverage for eligible insulin pump users, support access to advanced treatment technologies. Additionally, the presence of leading manufacturers, strong distribution networks, and continuous product innovation contribute to market growth. Increasing awareness of diabetes management, growing preference for convenient insulin administration, and rising demand for personalized treatment solutions further strengthen North America's market dominance.

insulin-delivery-device-market Region

INSULIN DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX

In the insulin delivery devices market matrix, Novo Nordisk (Denmark) (Star) and Embecta Corp. (US) (Star) lead with their unmatched global presence, strong brand recognition, and comprehensive portfolios of insulin delivery devices. Tandem Diabetes Care, Inc. (US) (Emerging Leader) is rapidly gaining traction with its insulin pumps.

insulin-delivery-device-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 15.61 Billion
Market Forecast in 2026 (Value) USD 16.92 Billion
Market Forecast in 2031 (Value) USD 26.37 Billion
Growth Rate CAGR of 9.3% from 2026-2031
Years Considered 2024-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Million/Billion), Volume (Thousand Units)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Type:
    • Insulin Pens
    • Insulin Pumps
    • Insulin Pen Needles
    • Insulin Syringes
    • Other Insulin Delivery Devices
  • By Application:
    • Type 1 Diabetes
    • Type 2 Diabetes
  • By End User:
    • Self/Home Healthcare
    • Hospitals & Diabetes Specialty Clinics.
Regional Scope North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: INSULIN DELIVERY DEVICES MARKET REPORT CONTENT GUIDE

insulin-delivery-device-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Company Information
  • Market share analysis, by region (North America and Europe), which provides market shares of the top 3-5 key players in the insulin delivery devices market
  • Competitive leadership mapping for established players in the US
Insights on market share analysis by country
Geographic Analysis
  • Further breakdown of the Rest of Europe insulin delivery devices market into Russia, Switzerland, Denmark, Austria, and others
  • Further breakdown of the Rest of Asia Pacific insulin delivery devices market into South Korea, Taiwan, and others
  • Further breakdown of the Rest of Latin America insulin delivery devices market into Argentina, Colombia, Chile, Ecuador, and others
Country-level demand mapping for new product launches and localization strategy planning

RECENT DEVELOPMENTS

  • September 2026 : Eli Lilly received FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering seven-day glucose control through KwikPen devices available in two high-concentration formulations.
  • May 2026 : Embecta acquired Owen Mumford, strengthening its drug-delivery portfolio, adding the Aidaptus auto-injector platform, and combining device innovation with global distribution and large-scale manufacturing to expand therapeutic coverage and operational efficiencies.
  • February 2026 : Medtronic launched its MiniMed Go Smart MDI system with the Simplera sensor in Europe, integrating InPen smart insulin pen and sensor data into one mobile app to support improved diabetes management for multiple-daily-injection users.
  • February 2025 : Sanofi received US FDA approval for Merilog, a biosimilar to NovoLog (insulin aspart). The approval was for both a 3 mL single-patient-use prefilled pen and a 10 mL multiple-dose vial.
  • January 2025 : Novo Nordisk A/S launched Awiqli (insulin icodec) injection in Japan in a prefilled FlexTouch pen.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
15
2
EXECUTIVE SUMMARY
 
 
 
 
3
PREMIUM INSIGHTS
 
 
 
 
4
MARKET OVERVIEW
This section summarizes market dynamics, key shifts, and high-impact trends shaping demand outlook.
 
 
 
 
 
4.1
INTRODUCTION
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
4.2.4
CHALLENGES
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
5
INDUSTRY TRENDS
Captures industry movement, adoption patterns, and strategic signals across key end-use segments and regions.
 
 
 
 
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
5.2.3
TRENDS IN THE DIABETES CARE DEVICES INDUSTRY
 
 
 
 
5.2.4
TRENDS IN THE INJECTABLE DRUG DELIVERY INDUSTRY
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
5.6
PRICING ANALYSIS (2023-2025)
 
 
 
 
 
 
5.6.1
AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023-2025)
 
 
 
 
5.6.2
AVERAGE SELLING PRICE TREND, BY PRODUCT (2023-2025)
 
 
 
 
5.6.3
AVERAGE SELLING PRICE TREND, BY REGION (2023-2025)
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
5.7.1
IMPORT SCENARIO
 
 
 
 
5.7.2
EXPORT SCENARIO
 
 
 
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
 
 
 
 
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
5.10
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
5.11
CASE STUDY ANALYSIS
 
 
 
 
5.12
IMPACT OF 2025 US TARIFFS–GLOBAL INSULIN DELIVERY DEVICES MARKET
 
 
 
 
 
 
5.12.1
INTRODUCTION
 
 
 
 
5.12.2
KEY TARIFF RATES
 
 
 
 
5.12.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.12.4
IMPACT ON REGIONS
 
 
 
 
 
5.12.4.1
US
 
 
 
 
5.12.4.2
EUROPE
 
 
 
 
5.12.4.3
ASIA PACIFIC
 
 
 
5.12.5
IMPACT ON END-USE INDUSTRIES
 
 
 
5.13
REIMBURSEMENT ANALYSIS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
 
 
 
 
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
6.3
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
6.4
PATENT ANALYSIS
 
 
 
 
 
6.5
FUTURE APPLICATIONS
 
 
 
 
6.6
IMPACT OF AI/GEN AI ON INSULIN DELIVERY DEVICES PROCEDURES
 
 
 
 
 
 
6.6.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
6.6.2
BEST PRACTICES IN INSULIN DELIVERY DEVICES PROCEDURES
 
 
 
 
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN THE INSULIN DELIVERY DEVICES MARKET
 
 
 
 
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
 
 
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
 
 
 
 
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
7.2
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
 
 
 
 
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
9
GLOBAL INSULIN DELIVERY DEVICES MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & IN VOLUME, THOUSAND UNITS)
 
 
 
 
 
9.1
INTRODUCTION
 
 
 
 
9.2
INSULIN PENS
 
 
 
 
 
9.2.1
REUSABLE INSULIN PENS
 
 
 
 
9.2.2
DISPOSABLE INSULIN PENS
 
 
 
9.3
INSULIN PUMPS
 
 
 
 
 
9.3.1
TETHERED INSULIN PUMPS
 
 
 
 
9.3.2
TUBELESS INSULIN PUMPS
 
 
 
9.4
INSULIN PEN NEEDLES
 
 
 
 
 
9.4.1
STANDARD INSULIN PEN NEEDLES
 
 
 
 
9.4.2
SAFETY INSULIN PEN NEEDLES
 
 
 
9.5
INSULIN SYRINGES
 
 
 
 
9.6
OTHER INSULIN DELIVERY DEVICES
 
 
 
10
GLOBAL INSULIN DELIVERY DEVICES MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
10.1
INTRODUCTION
 
 
 
 
10.2
TYPE 1 DIABETES
 
 
 
 
10.3
TYPE 2 DIABETES
 
 
 
11
GLOBAL INSULIN DELIVERY DEVICES MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
11.1
INTRODUCTION
 
 
 
 
11.2
SELF/HOME HEALTHCARE
 
 
 
 
11.3
HOSPITALS & DIABETES SPECIALTY CLINICS
 
 
 
12
GLOBAL INSULIN DELIVERY DEVICES MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & IN VOLUME, THOUSAND UNITS)
 
 
 
 
 
12.1
INTRODUCTION
 
 
 
 
12.2
NORTH AMERICA
 
 
 
 
 
12.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
12.2.2
US
 
 
 
 
12.2.3
CANADA
 
 
 
12.3
EUROPE
 
 
 
 
 
12.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
12.3.2
GERMANY
 
 
 
 
12.3.3
FRANCE
 
 
 
 
12.3.4
UK
 
 
 
 
12.3.5
ITALY
 
 
 
 
12.3.6
SPAIN
 
 
 
 
12.3.7
REST OF EUROPE
 
 
 
12.4
ASIA PACIFIC
 
 
 
 
 
12.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
12.4.2
CHINA
 
 
 
 
12.4.3
JAPAN
 
 
 
 
12.4.4
INDIA
 
 
 
 
12.4.5
AUSTRALIA
 
 
 
 
12.4.6
SOUTH KOREA
 
 
 
 
12.4.7
REST OF ASIA PACIFIC
 
 
 
12.5
LATIN AMERICA
 
 
 
 
 
12.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
12.5.2
BRAZIL
 
 
 
 
12.5.3
MEXICO
 
 
 
 
12.5.4
REST OF LATIN AMERICA
 
 
 
12.6
MIDDLE EAST & AFRICA
 
 
 
 
 
12.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
12.6.2
GCC COUNTRIES
 
 
 
 
12.6.3
REST OF MIDDLE EAST & AFRICA
 
 
13
COMPETITIVE LANDSCAPE
 
 
 
 
 
13.1
OVERVIEW
 
 
 
 
13.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
 
 
 
 
13.3
REVENUE SHARE ANALYSIS (2021-2025)
 
 
 
 
13.4
MARKET SHARE ANALYSIS (2025)
 
 
 
 
 
13.5
BRAND & PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
13.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
 
 
 
 
 
 
13.6.1
STARS
 
 
 
 
13.6.2
EMERGING LEADERS
 
 
 
 
13.6.3
PERVASIVE PLAYERS
 
 
 
 
13.6.4
PARTICIPANTS
 
 
 
 
13.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
 
 
 
 
 
13.6.5.1
COMPANY FOOTPRINT
 
 
 
 
13.6.5.2
REGION FOOTPRINT
 
 
 
 
13.6.5.3
PRODUCT FOOTPRINT
 
 
 
 
13.6.5.4
APPLICATION FOOTPRINT
 
 
 
 
13.6.5.5
END-USER FOOTPRINT
 
 
13.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
 
 
 
 
 
 
13.7.1
PROGRESSIVE COMPANIES
 
 
 
 
13.7.2
RESPONSIVE COMPANIES
 
 
 
 
13.7.3
DYNAMIC COMPANIES
 
 
 
 
13.7.4
STARTING BLOCKS
 
 
 
 
13.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
 
 
 
 
 
13.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
13.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
13.8
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
13.9
COMPETITIVE SCENARIO
 
 
 
 
 
13.9.1
PRODUCT LAUNCHES
 
 
 
 
13.9.2
DEALS
 
 
 
 
13.9.3
EXPANSIONS
 
 
14
COMPANY PROFILES
 
 
 
 
 
14.1
KEY PLAYERS
 
 
 
 
 
14.1.1
EMBECTA CORP. (FORMERLY BD DIABETES CARE BUSINESS)
 
 
 
 
14.1.2
NOVO NORDISK A/S
 
 
 
 
14.1.3
MEDTRONIC PLC
 
 
 
 
14.1.4
SANOFI
 
 
 
 
14.1.5
LILLY
 
 
 
 
14.1.6
YPSOMED HOLDINGS AG
 
 
 
 
14.1.7
TANDEM DIABETES CARE, INC
 
 
 
 
14.1.8
INSULET CORPORATION
 
 
 
 
14.1.9
BIOCON LIMITED
 
 
 
 
14.1.10
ROCHE DIABETES CARE
 
 
 
 
14.1.11
TERUMO CORPORATION
 
 
 
 
14.1.12
NIPRO CORPORATION
 
 
 
 
14.1.13
B. BRAUN SE
 
 
 
 
14.1.14
MANNKIND CORPORATION
 
 
 
 
14.1.15
WOCKHARDT LIMITED
 
 
 
14.2
OTHER PLAYERS
 
 
 
 
 
14.2.1
CEQUR SA
 
 
 
 
14.2.2
OWEN MUMFORD
 
 
 
 
14.2.3
MEDTRUM TECHNOLOGIES
 
 
 
 
14.2.4
HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
 
 
 
 
14.2.5
HASELMEIER GMBH, A MEDMIX LTD COMPANY
 
 
 
 
14.2.6
SOOIL DEVELOPMENT CO., LTD.
 
 
 
 
14.2.7
EOFLOW CO., LTD
 
 
 
 
14.2.8
DEBIOTECH SA
 
 
 
 
14.2.9
JIANGSU DELFU MEDICAL DEVICE CO., LTD
 
 
 
 
14.2.10
SUNGSHIM MEDICAL CO., LTD.
 
 
15
RESEARCH METHODOLOGY
 
 
 
 
 
15.1
RESEARCH DATA
 
 
 
 
 
15.1.1
SECONDARY DATA
 
 
 
 
 
15.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
15.1.2
PRIMARY DATA
 
 
 
 
 
15.1.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
15.1.2.2
KEY PRIMARY PARTICIPANTS
 
 
 
 
15.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
15.1.2.4
KEY INDUSTRY INSIGHTS
 
 
15.2
MARKET SIZE ESTIMATION
 
 
 
 
 
15.2.1
BOTTOM-UP APPROACH
 
 
 
 
15.2.2
TOP-DOWN APPROACH
 
 
 
 
15.2.3
BASE NUMBER CALCULATION
 
 
 
15.3
MARKET FORECAST APPROACH
 
 
 
 
 
15.3.1
SUPPLY SIDE
 
 
 
 
15.3.2
DEMAND SIDE
 
 
 
15.4
DATA TRIANGULATION
 
 
 
 
15.5
FACTOR ANALYSIS
 
 
 
 
15.6
RESEARCH ASSUMPTIONS
 
 
 
 
15.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
 
 
 
16
APPENDIX
 
 
 
 
 
16.1
DISCUSSION GUIDE
 
 
 
 
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
16.3
CUSTOMIZATION OPTIONS
 
 
 
 
16.4
RELATED REPORTS
 
 
 
 
16.5
AUTHOR DETAILS
 
 
 

Methodology

The study focused on estimating the current market size for the insulin delivery devices sector. Extensive secondary research was conducted to gather information about the insulin delivery devices industry. The next step involved validating the findings, assumptions, and estimates through primary research with industry experts across the value chain. Various approaches were used to estimate the total market size, including top-down and bottom-up methods. Next, market segmentation and data triangulation procedures were used to determine the sizes of the segments and subsegments within the insulin delivery devices market.

Secondary Research

The secondary research process relies heavily on secondary sources, including directories and databases such as Bloomberg Businessweek, Factiva, and D&B Hoovers. It also includes white papers, annual reports, investor presentations, company SEC filings, and publications from government sources. Notable examples include the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), the U.S. Census Bureau, the World Health Organization (WHO), the International Trade Administration (ITA), the Global Burden of Disease Study, and the Centers for Medicare and Medicaid Services (CMS). These sources were utilized to gather information for the global insulin delivery devices market study. The process aimed to provide insights into key players, market classification, and segmentation based on industry trends, down to the most detailed level. It also focused on significant developments from both market and technological perspectives. A comprehensive database of key industry leaders was also created using the information obtained through secondary research.

Primary Research

In this report's primary research, we interviewed sources from both the supply and demand sides to gather qualitative and quantitative information. The supply-side primary sources included industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from major companies and organizations in the insulin delivery devices market. On the demand side, primary sources included pharmaceutical companies, vaccination centers, hospitals and clinics, pharmacies, and university researchers and academics. This primary research was conducted to validate the market segmentation, identify key players, and gather insights on significant industry trends and market dynamics.

Insulin Delivery Devices Market 
 Size, and Share

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global insulin delivery devices market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global insulin delivery devices market was split into various segments and subsegments based on:

  • List of major players operating in the products market at the regional and/or country level
  • Product mapping of various insulin delivery device manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from insulin delivery devices (or the nearest reported business unit/product category)
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global insulin delivery devices market

The above data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Insulin Delivery Devices Market Top Down and Bottom Up Approach

Data Triangulation

After determining the overall size of the global insulin delivery devices market using the methodology above, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data were triangulated by analyzing macro indicators and regional trends from both demand- and supply-side participants

Market Definition

Insulin delivery devices are medical devices designed to deliver insulin, a hormone used to manage diabetes, into the body. These devices are primarily used by individuals with diabetes who require insulin therapy to regulate their blood sugar levels. Insulin pens, pumps, pen needles, and syringes are the most widely used delivery devices.

Key Stakeholders

  • Manufacturing companies of insulin pen needles, insulin pens, insulin pumps, insulin syringes, injectable insulin delivery devices, and diabetes supplies
  • Suppliers and distributors of insulin pen needles, insulin pens, insulin pumps, insulin syringes, injectable insulin delivery devices, and diabetes supplies
  • Pharmaceutical and biopharmaceutical companies
  • Healthcare service providers
  • Teaching hospitals and academic medical centers
  • Health insurance players
  • Government bodies/municipal corporations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists
  • Market research and consulting firms

Report Objectives

  • To describe, analyze, and forecast the global insulin delivery devices market based on type, end user, and region
  • To describe and forecast the insulin delivery devices market for key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the insulin delivery devices market
  • To strategically analyze the ecosystem, regulations, patenting trends, value chain, Porter’s five forces, and prices of the market under study
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
  • To profile the key players and comprehensively analyze their market shares and core competencies in the insulin delivery devices market
  • To analyze competitive developments such as partnerships, collaborations, acquisitions, product launches, expansions, and R&D activities in the insulin delivery devices market
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available customizations:

Based on the market data, MarketsandMarkets offers customizations to meet your company’s needs. The following customization options are available for the report:

GEOGRAPHIC ANALYSIS

  • Further breakdown of the Rest of Europe’s insulin delivery devices market into Switzerland, Denmark, and Austria, among others
  • Further breakdown of the Rest of Asia Pacific’s insulin delivery devices market into Vietnam and Taiwan, among others
  • Further breakdown of the Rest of Latin America’s insulin delivery devices market into Argentina, Colombia, Chile, and Ecuador
  • Further breakdown of the Southeast Asia insulin delivery devices market into Malaysia, Singapore, Australia, and New Zealand

COMPETITIVE LANDSCAPE ASSESSMENT

  • Market share analysis by region (North America and Europe), which provides market shares of the top 3–5 key players in the insulin delivery devices market
  • Competitive leadership mapping for established players in the US

 

Frequently Asked Questions (FAQ)

Which are the top industry players in the global insulin delivery devices market?

Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed (Switzerland), Medtronic, Plc (Ireland), Tandem Diabetes Care, Inc. (US), Sanofi (France), Eli Lilly and Company (US), and Insulet Corporation (US).

What are some of the major drivers for this market?

Growing prevalence of diabetes, technological advancements in insulin delivery devices, and government support and favorable reimbursement schemes.

Which end users have been included in the global insulin delivery devices market?

Hospitals & Clinics, Home Care Settings, and Other End Users.

Which product segments hold the largest market share in the insulin delivery devices market?

The insulin pens segment holds the largest market share.

Which region is the most lucrative in the insulin delivery devices market?

The Asia Pacific market is expected to witness the highest CAGR.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Insulin Delivery Devices Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Insulin Delivery Devices Market

THIS REPORT TELLS YOU

How big the Insulin Delivery Devices market is, and who leads it.

GROWTHIQ TELLS YOU NEW

Where your company should play next, and who is taking your share.

Get your company's view of this market. Free snapshot.

DMCA.com Protection Status
popup img